“a strong trend”

Furthermore, there was a strong trend to toward significant main effect of technique ( p = 0.0506), in which [La-] tended to be higher in PE-A when compared to TST (PE-A: 8.8 ± 4.1 = mmol∙L −1 , TST: 6.9 ± 3.1 mmol∙L −1 ), ( Figure 1 ). 3.3.

Further, a strong trend towards vascular invasion ( P =0.0506) was observed.

Grade 3/4 infections had a strong trend to occur more frequently with Cis/Doc (26% vs 9%, P =0.0507).

A strong trend for an increase in this measure was found in non-stressed C57BL/6 mice compared to non-stressed CBA mice ( p = 0.0507).

In contrast, we observed a strong trend toward cell loss in the CA1 region of GluA2 +/ECS(G) mice compared to WT littermates at 8-10 weeks (Fig. 4 b; mean ± SD, t = 2.3, df = 8, p = 0.0507 (unpaired t-test)).

retrospectively analyzed the data from dose-escalation trial RTOG 9406 and found a strong trend toward improved disease-free survival associated with long-term ADT ( P = 0.0507) in patients with PSA >20 who received a cumulative RT dose above 73.8 Gy. 14 A review by Feng et al . of the results of DERT (75–79.2 Gy) in patients with high-risk prostate cancer 13 found that addition of ADT decreased the 5-year cumulative incidence of biochemical failure and distant metastases (35% vs 13%, P < 0.001).

Control mCherry- and Gi-DREADD-injected mice did not significantly differ in any movement or distance variables measured, although the Gi-DREADD-injected mice showed a strong trend toward an increase in total distance travelled compared to controls (p = 0.0507) ( Fig. 5 C).

When adjusting for higher PSA (greater than 20) and for higher Gleason scores (>7), there was no obvious benefit for high risk patients when long-term ADT was added to EBRT at doses greater than 73.8 Gy, although there was a strong trend ( P = 0.0507).

RASS results ( 13 ) were consistent with those of ∼5 years DIRECT-Prevent 1 ( 14 ) where there was a strong trend ( P = 0.0508) for a reduction in the primary end point, time to two-steps or more DR progression, in type 1 diabetic patients with no DR at baseline who were randomized to candesartan.

At 4.5 mo of age, both male and female AhR CKO mice showed greater trabecular bone mass than WT littermates in the distal femoral metaphysis, evidenced by a reduction in trabecular separation ( p < .0001 for genotype), increased trabecular number ( p = .0190 for genotype), and a strong trend for increased trabecular bone volume fraction ( p = .0508 for genotype) as compared to sex-matched WT littermates.

Furthermore, there was a strong trend towards significance when comparing the frequency of LN in patients with different genotypes of rs117026326 or rs73366469 ( P = .051, .062, respectively).

Cox proportional hazard model showed that only surgery was an independent prognostic factor for survival ( P = 0.047), while tumor size showed a strong trend for statistical significance ( P = 0.051).

The Delong test confirmed that the AUC of the combined model was significantly larger than that of pre-treatment VD alone ( P = 0.038) and showed a strong trend toward superiority over pre-treatment VI alone ( P = 0.051).

During the subsequent period (d 15 to 35), there was a strong trend for improved feed efficiency in pigs fed lecithin diets ( P = 0.051) but there was no effect on feed intake and weight gain.

regarding composite disease progression, the Kaplan-Meier curves showed a strong trend toward risk reduction in the Azvudine group (Log-rank P = 0.051, Figure S2B).

Overall, statistical analysis showed a significant change in the IR of falls over time ( p = 0.003) for both groups with a strong trend for greater improvement in the 12-week group ( p = 0.051).

Interaction effects between ACE and A3B I/D polymorphisms on clinical characteristics No significant differences were found between the clinical characteristics of the carriers of both the ACE D and A3B I alleles and the remainder among the males or females of the 1199 adults, although there was a strong trend for aspartate aminotransferase in females (P = 0.051; Table 3 and Table 4 ).

Additionally, IC was lower with LH (3.5 ± 0.5 L) relative to UN (3.9 ± 0.6 L) at 35 min ( p = 0.022), and there was also a strong trend present at 45 min ( p = 0.051).

In the per-protocol analysis, there was a strong trend for HAMSB to reduce mean global small polyp numbers (0.79 FC; 95% CI, 0.62–1; P = 0.051).

While results for 2-year progression-free survival show a strong trend toward favoring rituximab treatment, they were not statistically significant, but only by a slight margin (HR 0.52, 95% CI 0.32–0.86, p = 0.051).

There was a significant main effect of test type (name detection/segregation detection: beta = −2.82, CI −4.24 to −1.41, p < 0.001) and a strong trend to a main effect of group (beta = −0.88, CI −1.77 to 0.003, p = 0.051).

When Mamu-A*01 animals were included, the dmLT group was not significantly protected, although there was a strong trend ( p = 0.051; Supplementary Figure S7B ), and the alum group was not protected ( p = 0.49; Supplementary Figure S7B ).

However, reading span correlated positively with performance accuracy in nonnative speakers ( r = 0.396, p = 0.022) but not in native speakers ( r = −0.023, p = 0.906); the difference of these correlations was a strong trend ( z = −1.632; p = 0.051).

Using the same statistical analysis of cortical damage in coronal sections 2–4 indicated a strong trend towards protection for tBH4-DCs compared to GFP-DC (P = 0.051).

Finally, pediatric patients with secondary PAD had a strong trend toward a lower mean anti-spike antibody response after two-dose vaccine series compared to primary PAD patients (767.1 vs. 3,679.2 U/mL; p=0.051) ( Figure 2 ).